| Mr Jeffrey Brian Pitman, GRNA | |
|
301 Yadkin St, Albemarle, NC 28001-3441 | |
| (704) 984-4469 | |
| Not Available |
| Full Name | Mr Jeffrey Brian Pitman |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 18 Years |
| Location | 301 Yadkin St, Albemarle, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699794909 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 157430 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanly Regional Medical Center | Albemarle, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cabarrus Gastroenterology Associates Pllc | 9436059649 | 34 |
| Chs Anesthesia Services Group Inc | 5799007324 | 548 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Entity Name | Carolina Digestive Health Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124052444 PECOS PAC ID: 1951209790 Enrollment ID: O20031230000650 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Entity Name | Cabarrus Gastroenterology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780790592 PECOS PAC ID: 9436059649 Enrollment ID: O20040113000342 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Entity Name | Cabarrus Gastroenterology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1346308517 PECOS PAC ID: 9436059649 Enrollment ID: O20070319000264 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Entity Name | Chs Anesthesia Services Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346649415 PECOS PAC ID: 5799007324 Enrollment ID: O20141209001856 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jeffrey Brian Pitman, GRNA 148 Cedarwood Pl Se, Concord, NC 28025-3720 Ph: (704) 788-4479 | Mr Jeffrey Brian Pitman, GRNA 301 Yadkin St, Albemarle, NC 28001-3441 Ph: (704) 984-4469 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.
A survey released in the U.S. has revealed that in the past year in excess of 2 million American teenagers experienced a serious bout of depression.
› Verified 2 days ago
Mrs. Anjana Menon Young, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 980-323-4590 Fax: 980-323-8269 | |
Mr. Scott Michael Winslow, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 704-984-4469 | |
Mrs. Jeanette Howell Burleson, C.R.N.A. Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 417 Park Ridge Rd, Albemarle, NC 28001 Phone: 704-986-4495 Fax: 704-983-3690 | |
Mrs. Kelly New, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 704-984-4469 | |
William R Dennis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin Street, Albemarle, NC 28001 Phone: 704-984-4000 | |
Mrs. Jessica Wing Steed, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 704-984-4469 |